Browse by category
Now showing items 21-40 of 197
-
Chloroquine and hydroxychloroquine: Current evidence for their effectiveness in treating COVID-19
(2020-03-25)Verdict: Several in vitro studies report antiviral activity of chloroquine and hydroxychloroquine against SARS-CoV-2. In vivo data, although promising, is currently limited to one study with considerable limitations. On ... -
Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: A pilot observational study
(2020-03)Background: We need an effective treatment to cure COVID-19 patients and to decrease virus carriage duration. Methods: We conducted an uncontrolled, non-comparative, observational study in a cohort of 80 relatively mildly ... -
Clinical Study of Mesenchymal Stem Cell Treatment for Acute Respiratory Distress Syndrome Induced by Epidemic Influenza A (H7N9) Infection: A Hint for COVID-19 Treatment
(2020-02-28)H7N9 viruses quickly spread between mammalian hosts and carry the risk of human-to-human transmission, as shown by the 2013 outbreak. Acute respiratory distress syndrome (ARDS), lung failure, and fulminant pneumonia are ... -
Clinical trials for the prevention and treatment of COVID ‐19: current state of play
(2020-06-27)Since coronavirus disease 2019 (COVID ‐19) emerged in Wuhan, China in December 2019 and spread around the world, over 1100 clinical studies have been registered globally on clinical trials registries, including over 500 ... -
Collecting and evaluating convalescent plasma for COVID‐19 treatment: why and how
(2020-04-02)Plasma provided by COVID‐19 convalescent patients may provide therapeutic relief as the number CODID‐19 cases escalate steeply world‐wide. Prior findings in various viral respiratory diseases including SARS‐CoV related ... -
Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis
(2020-03-13)Background: The coronavirus disease 2019 (COVID-19) outbreak is evolving rapidly worldwide. Objective: To evaluate the risk of serious adverse outcomes in patients with COVID-19 by stratifying the comorbidity status. ... -
Comparative efficacy and safety of pharmacological interventions for the treatment of COVID-19: A systematic review and network meta-analysis
(2020-12-30)Background: Numerous clinical trials and observational studies have investigated various pharmacological agents as potential treatment for Coronavirus Disease 2019 (COVID-19), but the results are heterogeneous and sometimes ... -
Concentration-dependent mortality of chloroquine in overdose
(2020-04-29)Background: Hydroxychloroquine and chloroquine have been used extensively in malaria and rheumatological conditions. Although generally safe and well tolerated they are potentially lethal in overdose. These two drugs are ... -
Controversial treatments: An updated understanding of the coronavirus disease 2019
(2020-03-26)An outbreak of severe acute respiratory syndrome‐related coronavirus 2 infection has posed significant threats to international health and the economy. In the absence of specific treatment for this virus, there is an urgent ... -
Convalescent plasma or hyperimmune immunoglobulin for people with COVID‐19: a rapid review
(2020-05-14)Background: Convalescent plasma and hyperimmune immunoglobulin may reduce mortality in patients with respiratory virus diseases, and are currently being investigated in trials as a potential therapy for coronavirus disease ... -
Convalescent plasma transfusion for the treatment of COVID‐19: Systematic review
(2020-05-01)Background: The recent emergence of COVID‐19 pandemic has reassessed the usefulness of historic convalescent plasma transfusion (CPT). This review was conducted to evaluate the effectiveness of CPT therapy in COVID‐19 ... -
Convalescent plasma treatment of severe COVID-19: A matched control study
(2020-05-22)Background Since December 2019, Coronavirus Disease 2019 (COVID-19) has become a global pandemic, causing mass morbidity and mortality. Prior studies in other respiratory infections suggest that convalescent plasma transfusion ... -
Corticosteroid administration for viral pneumonia: COVID-19 and beyond
(2020-06-19)Background: Corticosteroids are commonly used as adjuvant therapy for acute respiratory distress syndrome by many clinicians because of their perceived anti-inflammatory effects. However, for patients with severe viral ... -
Corticosteroid therapy for critically ill patients with COVID-19: A structured summary of a study protocol for a prospective meta-analysis of randomized trials
(2020-08-24)Primary objective: To estimate the effect of corticosteroids compared with usual care or placebo on mortality up to 28 days after randomization. Secondary objectives: To examine whether the effect of corticosteroids compared ... -
Could Intravenous Immunoglobulin Collected from Recovered Coronavirus Patients Protect against COVID-19 and Strengthen the Immune System of New Patients?
(2020-03-25)The emergence of the novel coronavirus in Wuhan, China, which causes severe respiratory tract infections in humans (COVID-19), has become a global health concern. Most coronaviruses infect animals but can evolve into strains ... -
COVID-1. Informal consultation on the potential role of chloroquine in the clinical management of COVID 19 infection, draft 13 March 2020
(2020-03-13)Currently, there are no therapeutic agents licensed and available for the treatment of COVID 19. On the 27th of January, WHO convened a meeting of experts to examine the available evidence and prioritize promising therapeutic ... -
COVID-19 and psoriasis: biologic treatment and challenges
(2020-07-06)Background: There is concern about susceptibility of psoriatic patients on biologics to coronavirus disease 2019 (COVID-19) and its clinical course. Purpose: The aims of present review were to determine whether the biologic ... -
COVID-19 virus may have neuroinvasive potential and cause neurological complications: a perspective review
(2020-05-16)Coronavirus disease 2019 (COVID-19) was reported at the end of 2019 in China for the first time and has rapidly spread throughout the world as a pandemic. Since COVID-19 causes mild to severe acute respiratory syndrome, ... -
COVID-19: A Brief Overview of the Discovery Clinical Trial
(2020-04-10)COVID-19 (coronavirus disease 2019) is a worldwide outbreak of pneumonia and acute respiratory distress syndrome. It is unambiguously linked to the human–human transmission of a novel coronavirus. Mutagenomic analyses ... -
Covid2019 / SARSCoV2 coronavirus antivirals
(2020-04-20)Includes: Interferons, Nucleoside analogs, Protease inhibitors, Furin Convertase Cleavage inhibitors, Reverse transcriptase inhibitors, RNA Polymerase/Synthesis Inhibitors, Neuraminidase inhibitors, Angiotensin II receptor ...